Iovance: The Company Makes It Hard To Estimate Revenue Growth [Seeking Alpha]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Seeking Alpha
Proleukin revenues could be a leading indicator for Amtagvi revenues, but the company also supplied a new distributor in Q4'24, making it hard to judge Q1'25 Amtagvi growth. Obsidian Therapeutics represents a relevant competitor with a cell therapy called OBX-115, that has potential advantages over lifileucel, although IOVA has its own next-gen therapies in development. Judging by the price action, and current valuation of Iovance Biotherapeutics ( NASDAQ: IOVA ), it seems the market isn't entirely convinced by the company's FY2025 total product revenue guidance of $450M-$475M. My previous article on IOVA in December rated the Recommended For You Comments Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- 1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street [Yahoo! Finance]Yahoo! Finance
- 3 Growth Stocks Wall Street Might Be Sleeping On -- But I'm Not [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? [Yahoo! Finance]Yahoo! Finance
- Enrich Biosystems Welcomes Dr. Laszlo Radvanyi as Scientific Advisor [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/27/25 - Beat
IOVA
Sec Filings
- 3/18/25 - Form 4
- 3/7/25 - Form 4
- 3/7/25 - Form 4
- IOVA's page on the SEC website